Phar & Vide

Phar & Vide Life Sciences Private Limited is an Indian pharmaceutical exporter headquartered in Chennai, Tamil Nadu. Established on May 1, 2025, the company is registered under the Corporate Identification Number (CIN) U46497TN2025PTC180063. The authorized capital stands at ₹1.5 million, with a paid-up capital of ₹0.3 million. The registered office is located at No 151,152/203, Agurchand Mansion, Mount Road, Chennai, Tamil Nadu 600002.

The company's ownership structure comprises directors Prakash Chordia and Hastimal Chordia, both appointed on May 1, 2025. Phar & Vide Life Sciences Private Limited is an unlisted private limited company, indicating it is not publicly traded.

In the fiscal year 2022-2026, Phar & Vide reported a total export value of $1.0 million USD, with 32 shipments across five products in three therapeutic categories. The top five exported products include Serum, Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide, collectively accounting for 100% of the company's export portfolio.

Specific details regarding Phar & Vide's manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company's registered office is situated in Chennai, Tamil Nadu, but there is no publicly available information confirming the presence of manufacturing plants at this location. Given the company's focus on exporting finished pharmaceutical formulations, it is likely that manufacturing operations are conducted at facilities compliant with Good Manufacturing Practices (GMP) standards, though exact details remain undisclosed.

Phar & Vide Life Sciences Private Limited is led by directors Prakash Chordia and Hastimal Chordia, both appointed on May 1, 2025. As the company is unlisted and relatively new, detailed profiles of these individuals, including their professional backgrounds and roles within the organization, are not publicly available. The absence of publicly accessible information suggests that the company may be in the early stages of its operations, with leadership roles and responsibilities still being established.

Phar & Vide Life Sciences Private Limited's export activities, as reported in the fiscal year 2022-2026, include a total export value of $1.0 million USD across 32 shipments. The company's product portfolio comprises five finished pharmaceutical formulations in three therapeutic categories. However, specific details regarding the regulatory approvals, market access status, and presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed. The absence of this information indicates that Phar & Vide may not yet have established a significant presence in these markets or that such details have not been made publicly available.

Phar & Vide Life Sciences Private Limited's export activities, as reported in the fiscal year 2022-2026, include a total export value of $1.0 million USD across 32 shipments. The company's product portfolio comprises five finished pharmaceutical formulations in three therapeutic categories. However, specific details regarding the company's penetration into emerging markets such as Africa, Latin America, and Southeast Asia, as well as the status of WHO prequalification enabling access to these regions, are not publicly disclosed. The absence of this information suggests that Phar & Vide may not yet have established a significant presence in these markets or that such details have not been made publicly available.

Phar & Vide Life Sciences Private Limited's export portfolio is entirely concentrated in five products, accounting for 100% of its export value. This indicates a high level of portfolio concentration, which may expose the company to risks associated with market fluctuations and regulatory changes affecting these specific products. The company's strategic direction appears to be focused on a narrow product range, potentially limiting its ability to diversify and mitigate risks associated with market concentration. However, without publicly available information on the company's future plans or strategic initiatives, it is challenging to assess its long-term geographic strategy and potential for diversification.

Specific details regarding Phar & Vide Life Sciences Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly disclosed. The absence of this information suggests that the company may not yet have established a significant presence in the U.S. market or that such details have not been made publicly available. Given the company's focus on exporting finished pharmaceutical formulations, it is likely that any interactions with the FDA would pertain to compliance with U.S. regulatory standards for imported pharmaceutical products.

Specific details regarding Phar & Vide Life Sciences Private Limited's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed. The absence of this information suggests that the company may not yet have obtained these certifications or that such details have not been made publicly available. Given the company's focus on exporting finished pharmaceutical formulations, obtaining WHO prequalification and EU GMP certification would be essential for accessing international markets and ensuring product quality and safety.

Specific details regarding Phar & Vide Life Sciences Private Limited's compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations, including manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs), are not publicly disclosed. The absence of this information suggests that the company may not yet have obtained these regulatory approvals or that such details have not been made publicly available. Given the company's focus on exporting finished pharmaceutical formulations, adherence to CDSCO regulations would be essential for ensuring product quality and safety for both domestic and international markets.

As of March 28, 2026, there are no publicly available records indicating that Phar & Vide Life Sciences Private Limited has been subject to any regulatory actions, such as FDA Form 483 observations, warning letters, or import alerts. The absence of such records may be due to the company's relatively recent establishment and limited public exposure. It is important for the company to maintain compliance with all applicable regulatory standards to ensure the safety and efficacy of its pharmaceutical products.

Phar & Vide Life Sciences Private Limited operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not publicly disclosed, the Indian pharmaceutical export sector is characterized by numerous established companies with diverse product portfolios and global market reach. The company's portfolio concentration, with its top five products accounting for 100% of its export value, may limit its ability to compete effectively against larger, more diversified competitors. To enhance its competitive position, Phar & Vide may consider expanding its product range and exploring new markets.

Phar & Vide Life Sciences Private Limited's key differentiator lies in its focus on exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. This specialization allows the company to cater to the growing global demand for ready-to-use pharmaceutical products. However, the company's portfolio concentration, with its top five products accounting for 100% of its export value, may limit its ability to diversify and mitigate risks associated with market fluctuations. Expanding its product portfolio and obtaining international certifications could further strengthen its competitive advantage.

Phar & Vide Life Sciences Private Limited's current strategic direction appears to be focused on exporting finished pharmaceutical formulations, with a portfolio concentrated in five products. The company's unlisted status and recent establishment suggest that it is in the early stages of its strategic development. To enhance its market presence and mitigate risks associated with portfolio concentration, the company may consider diversifying its product range, obtaining international certifications, and exploring new markets. A clear strategic plan will be essential for the company's long-term growth and success in the competitive pharmaceutical export sector.

Phar & Vide Life Sciences Private Limited's export activities, as reported in the fiscal year 2022-2026, include a total export value of $1.0 million USD across 32 shipments. The company's product portfolio comprises five finished pharmaceutical formulations in three therapeutic categories. However, specific details regarding the company's track record, export volume consistency, and reliability indicators are not publicly disclosed. The absence of this information suggests that the company may be in the early stages of its operations, with limited public exposure. Prospective partners and clients may consider conducting direct due diligence to assess the company's reliability and performance.

Prospective importers should verify the following certifications to ensure compliance with international standards:

• FDA Registration: Confirm that the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

• WHO-GMP Certification: Ensure that the company holds a